The conditions for prescribing and dispensing certain biotherapies used in the treatment of chronic inflammatory diseases in rheumatology, gastroenterology, dermatology and ophthalmology just changed by the National Medicines Safety Agency (ANSM). This measure will facilitate the care pathway for patients by allowing them to be taken care of over the long term by city doctors after the initiation of treatment in a hospital environment.
What drugs are involved?
This measure concerns certain medicinal products indicated in the treatment of chronic inflammatory rheumatism, psoriasis, from inflammatory bowel disease and certain eye conditions:
- Adalimumab: Humira and biosimilars (Amgevita, Halimatoz, Hulio, Hyrimoz, Imraldi)
- Etanercept: Enbrel and biosimilars (Benepali, Erelzi, Lifmior)
- Golimumab: Simponi
- Certolizumab pegol: Cimzia
- Anakinra: Kineret
In practice, for these drugs, the first prescription must always be established by a specialist in a hospital setting, but renewals may be prescribed by a specialist in town.
Read also :
Ulcerative colitis: a little-known disease
Back pain: what if it was an inflammatory disease?
